KromaTiD Inc, Longmont, Colo, has announced that after successfully meeting phase 1 grant milestones, the company has been awarded a phase 2 Small Business Innovation Research (SBIR) grant from the US National Human Genome Research Institute (NHGRI).

KromaTiD is seeking to transform the fields of gene editing, undiagnosed disease, and oncology through the discovery and detection of complex genetic changes. The SBIR program supports scientific exploration and technological innovation by incentivizing small businesses to engage in commercial research and development.

The combined grants, totaling $900,000, will fund further development of an automated, whole-genome directional genomic hybridization (dGH) platform. KromaTiD’s proprietary dGH technology is a single-cell structural genomics technology, uniquely capable of the de novo measurement of random, low-frequency, and complex structural variations. By directly reading the chromosomal structure of many individual cells, dGH provides unique, quantitative structural genomic data unavailable by other methods.

Christopher Tompkins, KromaTiD.

Christopher Tompkins, KromaTiD.

“We are very excited by our progress toward automating our platform and the prospect of providing our customers with a whole-genome, high-resolution structural genomic solution,” says Christopher Tompkins, PhD, KromaTiD’s president and chief technology officer. “Funding from the NHGRI has been critical in positioning our company to meet the growing structural genomic demands of our pharma, biopharma, and therapeutic gene-editing company customers.”

For further information, visit KromaTiD.

Featured image: KromaTiD dGH chromosome.